Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial New Device Coverage Key For Small Firms, AbioMed Exec Says

This article was originally published in The Gray Sheet

Executive Summary

A provision authorizing Medicare to cover routine costs of clinical trials for investigational devices likely will be attached to prescription drug legislation due after lawmakers return from the Memorial Day recess June 2
Advertisement

Related Content

Device Industry Extols Medicare Passage Despite Competitive Bidding Thorn
Device Industry Extols Medicare Passage Despite Competitive Bidding Thorn
Tax Cuts, Rx Debate May Stymie Medicare Coverage Reforms – Rep. Cardin
Tax Cuts, Rx Debate May Stymie Medicare Coverage Reforms – Rep. Cardin
Abiomed AbioCor Proxy Consent Policy Will Hasten Pace Of Trial Enrollment
J&J’s Longstreet: Medicare, Global Payment Reforms Move To Front Of Queue
HHS IG Notice On Clinical Trials Coverage Overlooks Private Studies
HCFA Rolls Out "Generous" Clinical Trials Coverage Policy
Advertisement
UsernamePublicRestriction

Register

MT018424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel